Researchers have found that RP2 – a modified version of the herpes simplex virus – has showed signs of effectiveness in a quarter of patients with a range of advanced cancers.
Patients on the trial had cancers including skin, oesophageal and head and neck cancer and had tried other treatments, including checkpoint inhibitor immunotherapy.
The early findings – presented at the 2022 European Society for Medical Oncology Congress (ESMO) – suggest cancer-killing viruses could potentially offer hope to some patients where other forms of immunotherapy have not worked…
